Core Viewpoint - MicroPort CardioFlow-B (02160) has seen a significant stock increase, with a rise of over 10% and a current price of 1.25 HKD, reflecting strong market interest and positive developments in the company's product offerings [1] Group 1: Product Development and Market Expansion - The VitaFow series transcatheter aortic valves and delivery systems have been introduced in 35 countries, with nearly 1,300 implants to date [1] - The projected implant volume for 2025 is expected to exceed 850 cases, representing a nearly 350% increase compared to 2024 [1] - The second half of 2025 is anticipated to see over 170% growth in implant volume compared to the first half [1] Group 2: Strategic Developments - On December 21, the company announced a strategic merger with MicroPort Cardiac Rhythm Management, which is expected to enhance the company's resilience against risks by diversifying beyond a single market segment [1] - The merger will provide access to a more mature global sales network, facilitating accelerated expansion into overseas markets [1] - The collaboration aims to leverage both companies' research and development capabilities in medical devices to create a global platform for heart failure treatment [1]
港股异动 | 微创心通-B(02160)再涨超10% TAVI产品全年植入量同比增长近350%